Navigation Links
Indevus Announces Allergan as New Partner for SANCTURA Brand
Date:9/19/2007

>

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA, for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering.

About SANCTURA and SANCTURA XR

SANCTURA(R) and SANCTURA(R) XR belong to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax detrusor smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or unstable detrusor muscle function is believed to be the cause of overactive bladder.

SANCTURA and SANCTURA XR possess a quaternary ammonium structure that may be instrumental in the low incidence of CNS side-effects. At therapeutic concentrations in vitro, SANCTURA and SANCTURA XR do not interact with drugs metabolized by the Cytochrome P-450 system, a metabolic pathway commonly associated with drug-drug interactions, and the majority of the absorbed dose is excreted largely unchanged into the urine.

Patients who have urinary retention, gastric retention, uncontrolled narrow-angle glaucoma or hypersensitivity to any of the ingredients of SANCTURA or SANCTURA XR should not use SANCTURA or SANCTURA XR.

Prescribing Information

Complete prescribing information for SANCTURA XR is available from the Company upon request.

Forward Looking Statements'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 Today, Nerium International, a leader ... of its “Reflect Your Youth” contest, an effort launched ... a difference in their skin since using Nerium’s product ... on life as a result of their newfound confidence. ... effort by Nerium International to inspire conversations focused on ...
(Date:10/25/2014)... , October 24, 2014 Oramed ... pharmaceutical company focused on the development of oral drug ... Nadav Kidron will present at FireRock Capital,s Micro-Cap ... Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: ... New York City , ...
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... launch of a new series of web-based training programs for professionals ... courses are one hour in duration and designed specifically for the ... ... Salt Lake City, Utah (PRWEB) December 11, 2008 -- ...
... Schering-Plough Corporation (NYSE: SGP ) today declared a quarterly ... made on Feb. 27, 2009, to shareholders of record at the ... 30, 2008, there were 1,626,234,628 common shares outstanding. , ... declared a quarterly dividend of $3.75 per share on the 2007 ...
... of Hematology Annual Meeting , , ... ACEL ) today announced that American Society of Hematology ... Abstract 4205 & 2008 112: Abstract 4010) report that ONCONASE ... leukemia (CLL) and acute myeloblastic leukemia (AML) cells alone as ...
Cached Biology Technology:McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 2McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5
(Date:10/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended September 30, 2014. Revenue for the ... 40% compared to $4.3 million in the same quarter last ... $4.1 million compared to $1.0 million in the third quarter ... period was primarily due to: i) a $1.0 million increase ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... CAFebruary 23, 2014The power of regenerative medicine now allows ... resemble heart cells, pancreas cells and even neurons. However, ... crucial prerequisite for life-saving therapieshas proven far more difficult. ... University of California, San Francisco (UCSF), have made an ...
... New Rochelle, NY, February 20, 2014A new era of manufacturing ... manufacturing technologies are set to usher in the next generation ... of this groundbreaking new technology, Mary Ann Liebert, Inc., publishers ... new peer-reviewed journal 3D Printing and Additive Manufacturing ...
... [Brown University] Here are two facts that make ... ecology research, and they are very sensitive to temperature. ... a bellwether community of two barnacle species in Chile ... these two species if they experimentally changed temperature. In ...
Cached Biology News:Scientists transform skin cells into functioning liver cells 2Scientists transform skin cells into functioning liver cells 33-D Printing and Additive Manufacturing: Preview issue of groundbreaking peer-reviewed journal now available 2Temperature and ecology: Rival Chilean barnacles keep competition cool 2Temperature and ecology: Rival Chilean barnacles keep competition cool 3
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
... PCR carry-over contamination, which prevents false ... products from previous PCR amplifications without ... improves amplification ,Optimized for use with ... instrument systems , The GeneAmp PCR ...
... a-Amylase is an enzyme that catalyzes ... of maltose, maltotriose, and dextrins. The,level ... the human body is of,clinical significance ... including,pancreatitis and diabetes; plant and microbial ...
... Labsystems Wellmix is a high-quality four-place microplate ... The shaking speed is adjustable from 100 ... speed and a small orbit ensure effective ... time is quick and easy to set ...
Biology Products: